Recent studies have reported that the emergence of hormone therapy resistance in ER+ breast cancers can arise through four predominant mechanisms including ESR1 mutations (18%), altered MAPK signaling (13%), MYC or transcription factor activation (9%), and other/unknown factors (60%) [31]. Here, MYC is linked to breast carcinoma.